查看文章

Objective:

The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated the efficacy and safety of targeting a systolic blood pressure (SBP) of< 120 mmHg compared to< 140 mmHg in non-diabetic patients at increased cardiovascular (CV) risk. Scientific evidence, however, suggests a lower limit of diastolic BP (DBP) beyond which risk of events outweighs potential benefits, particularly in subjects with CV disease (CVD) and chronic kidney disease (CKD). We evaluated the risk of events in the SPRINT trial overall and in subgroups with preexisting CVD and CKD, according to different DBP levels.

Design and method:

Participants with not-available data were excluded from the analyses. DBP (±SD) throughout the entire follow-up time was calculated for each patient. Patients were then categorized into 5 groups (DBP< 60 mmHg, 60–69 mmHg, 70–79 mmHg [reference], 80–89 mmHg,>= 90 mmHg); hazard ratio …